Cyclacel Pharmaceuticals (CYCC) Registration Filing summary

Company overview and business model

• Operates as a clinical-stage biopharmaceutical company focused on developing cancer medicines targeting cell cycle, epigenetics, and mitosis biology.

• Lead program is plogosertib (PLK1 inhibitor) in Phase 1/2 trials for solid tumors and hematological malignancies.

• Recently shifted focus solely to plogosertib, discontinuing other programs and liquidating its UK subsidiary.

• Entered into a share exchange agreement to acquire Fitters Sdn. Bhd., diversifying into new business areas.

Financial performance and metrics

• As of March 31, 2025, had $3.5 million in cash and equivalents, with $3.0 million raised in Q2 2025 private placement.

• Net loss for 2024 was $11.2 million, with an accumulated deficit of $440.5 million as of March 31, 2025.

• Fitters Sdn. Bhd. reported a net loss of $92,086 for the year ended March 31, 2025, on $1.9 million in revenue.

• Pro forma combined net loss for 2024 would have been $11.3 million.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling shareholders; proceeds from warrant exercises (up to $17.6 million) would be used for working capital.

• Recent capital raises used for general corporate and operating purposes.